188 related articles for article (PubMed ID: 37823709)
21. Clinical characteristics of gastrointestinal immune-related adverse events of immune checkpoint inhibitors and their association with survival.
Yamada K; Sawada T; Nakamura M; Yamamura T; Maeda K; Ishikawa E; Iida T; Mizutani Y; Kakushima N; Ishikawa T; Furukawa K; Ohno E; Honda T; Kawashima H; Ishigami M; Furune S; Hase T; Yokota K; Maeda O; Hashimoto N; Akiyama M; Ando Y; Fujishiro M
World J Gastroenterol; 2021 Nov; 27(41):7190-7206. PubMed ID: 34887637
[TBL] [Abstract][Full Text] [Related]
22. Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer.
Dolladille C; Ederhy S; Sassier M; Cautela J; Thuny F; Cohen AA; Fedrizzi S; Chrétien B; Da-Silva A; Plane AF; Legallois D; Milliez PU; Lelong-Boulouard V; Alexandre J
JAMA Oncol; 2020 Jun; 6(6):865-871. PubMed ID: 32297899
[TBL] [Abstract][Full Text] [Related]
23. Immune-related adverse events as potential surrogates of immune checkpoint inhibitors' efficacy: a systematic review and meta-analysis of randomized studies.
Amoroso V; Gallo F; Alberti A; Paloschi D; Ferrari Bravo W; Esposito A; Cosentini D; Grisanti S; Pedersini R; Petrelli F; Berruti A
ESMO Open; 2023 Apr; 8(2):100787. PubMed ID: 36842300
[TBL] [Abstract][Full Text] [Related]
24. Eosinophil may be a predictor of immune-related adverse events induced by different immune checkpoint inhibitor types: A retrospective multidisciplinary study.
Tasaki Y; Sugiyama Y; Hamamoto S; Naiki T; Uemura T; Yokota K; Kawakita D; Nakamura M; Ogawa R; Shimura T; Mimura Y; Hotta Y; Odagiri K; Ito N; Iida M; Kimura Y; Komatsu H; Kataoka H; Takiguchi S; Morita A; Iwasaki S; Okuda K; Niimi A; Yasui T; Furukawa-Hibi Y
Cancer Med; 2023 Dec; 12(24):21666-21679. PubMed ID: 37986680
[TBL] [Abstract][Full Text] [Related]
25. Temporal Trends and Outcomes Among Patients Admitted for Immune-Related Adverse Events: A Single-Center Retrospective Cohort Study from 2011 to 2018.
Molina GE; Zubiri L; Cohen JV; Durbin SM; Petrillo L; Allen IM; Murciano-Goroff YR; Dougan M; Thomas MF; Faje AT; Rengarajan M; Guidon AC; Chen ST; Okin D; Medoff BD; Nasrallah M; Kohler MJ; Schoenfeld SR; Karp Leaf RS; Sise ME; Neilan TG; Zlotoff DA; Farmer JR; Mooradian MJ; Bardia A; Mai M; Sullivan RJ; Semenov YR; Villani AC; Reynolds KL
Oncologist; 2021 Jun; 26(6):514-522. PubMed ID: 33655682
[TBL] [Abstract][Full Text] [Related]
26. Relationship between Programmed Cell Death Protein Ligand 1 Expression and Immune-related Adverse Events in Non-small-cell Lung Cancer Patients Treated with Pembrolizumab.
Sugisaka J; Toi Y; Taguri M; Kawashima Y; Aiba T; Kawana S; Saito R; Aso M; Tsurumi K; Suzuki K; Shimizu H; Ono H; Domeki Y; Terayama K; Nakamura A; Yamanda S; Kimura Y; Honda Y; Sugawara S
JMA J; 2020 Jan; 3(1):58-66. PubMed ID: 33324776
[TBL] [Abstract][Full Text] [Related]
27. Patterns and outcomes of immune-related adverse events in solid tumor patients treated with immune checkpoint inhibitors in Thailand: a multicenter analysis.
Ngamphaiboon N; Ithimakin S; Siripoon T; Sintawichai N; Sriuranpong V
BMC Cancer; 2021 Nov; 21(1):1275. PubMed ID: 34823493
[TBL] [Abstract][Full Text] [Related]
28. Immune-related adverse events in checkpoint blockade: Observations from human tissue and therapeutic considerations.
Williams KC; Gault A; Anderson AE; Stewart CJ; Lamb CA; Speight RA; Rajan N; Plummer R; Pratt AG
Front Immunol; 2023; 14():1122430. PubMed ID: 36776862
[TBL] [Abstract][Full Text] [Related]
29. Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma.
Owen CN; Bai X; Quah T; Lo SN; Allayous C; Callaghan S; Martínez-Vila C; Wallace R; Bhave P; Reijers ILM; Thompson N; Vanella V; Gerard CL; Aspeslagh S; Labianca A; Khattak A; Mandala M; Xu W; Neyns B; Michielin O; Blank CU; Welsh SJ; Haydon A; Sandhu S; Mangana J; McQuade JL; Ascierto PA; Zimmer L; Johnson DB; Arance A; Lorigan P; Lebbé C; Carlino MS; Sullivan RJ; Long GV; Menzies AM
Ann Oncol; 2021 Jul; 32(7):917-925. PubMed ID: 33798657
[TBL] [Abstract][Full Text] [Related]
30. Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment.
Muir CA; Clifton-Bligh RJ; Long GV; Scolyer RA; Lo SN; Carlino MS; Tsang VHM; Menzies AM
J Clin Endocrinol Metab; 2021 Aug; 106(9):e3704-e3713. PubMed ID: 33878162
[TBL] [Abstract][Full Text] [Related]
31. The Inconsistent and Inadequate Reporting Of Immune-Related Adverse Events in PD-1/PD-L1 Inhibitors: A Systematic Review of Randomized Controlled Clinical Trials.
Xie T; Zhang Z; Qi C; Lu M; Zhang X; Li J; Shen L; Peng Z
Oncologist; 2021 Dec; 26(12):e2239-e2246. PubMed ID: 34396642
[TBL] [Abstract][Full Text] [Related]
32. Impact of Immune-Related Adverse Events on Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma.
Ng KYY; Tan SH; Tan JJE; Tay DSH; Lee AWX; Ang AJS; Wong LWJ; Choo SP; Tai DW; Lee JJX
Liver Cancer; 2022 Jan; 11(1):9-21. PubMed ID: 35222504
[TBL] [Abstract][Full Text] [Related]
33. Association between skin immune-related adverse events (irAEs) and multisystem irAEs during PD-1/PD-L1 inhibitor monotherapy.
Yamaguchi A; Saito Y; Narumi K; Furugen A; Takekuma Y; Shinagawa N; Shimizu Y; Dosaka-Akita H; Sugawara M; Kobayashi M
J Cancer Res Clin Oncol; 2023 Apr; 149(4):1659-1666. PubMed ID: 36346501
[TBL] [Abstract][Full Text] [Related]
34. Immune-Related Adverse Event-Related Adrenal Insufficiency Mediates Immune Checkpoint Inhibitors Efficacy in Cancer Treatment.
Zhang S; Wu J; Zhao Y; Zhang J; Zhang X; Wu C; Zhang Z; Guo Z
Cancer Manag Res; 2024; 16():151-161. PubMed ID: 38501053
[TBL] [Abstract][Full Text] [Related]
35. Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade-a worldwide perspective.
Gougis P; Jochum F; Abbar B; Dumas E; Bihan K; Lebrun-Vignes B; Moslehi J; Spano JP; Laas E; Hotton J; Reyal F; Hamy AS; Salem JE
EClinicalMedicine; 2024 Apr; 70():102536. PubMed ID: 38560659
[TBL] [Abstract][Full Text] [Related]
36. Distinct Immune Signatures Indicative of Treatment Response and Immune-Related Adverse Events in Melanoma Patients under Immune Checkpoint Inhibitor Therapy.
Reschke R; Gussek P; Boldt A; Sack U; Köhl U; Lordick F; Gora T; Kreuz M; Reiche K; Simon JC; Ziemer M; Kunz M
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360781
[TBL] [Abstract][Full Text] [Related]
37. Associations between patient and disease characteristics and severe adverse events during immune checkpoint inhibitor treatment: An observational study.
Basak EA; Vermeer NS; de Joode K; Hurkmans DP; Velthuis DEM; Oomen-de Hoop E; Schreurs MWJ; Bins S; Koolen SLW; Debets R; van der Veldt AAM; Aerts JGJV; Joosse A; Mathijssen RHJ
Eur J Cancer; 2022 Oct; 174():113-120. PubMed ID: 35988409
[TBL] [Abstract][Full Text] [Related]
38. Melanoma patients with immune-related adverse events after immune checkpoint inhibitors are characterized by a distinct immunological phenotype of circulating T cells and M-MDSCs.
Lepper A; Bitsch R; Özbay Kurt FG; Arkhypov I; Lasser S; Utikal J; Umansky V
Oncoimmunology; 2023; 12(1):2247303. PubMed ID: 37593676
[TBL] [Abstract][Full Text] [Related]
39. Checkpoint-blocker-induced autoimmunity is associated with favourable outcome in metastatic melanoma and distinct T-cell expression profiles.
Ye W; Olsson-Brown A; Watson RA; Cheung VTF; Morgan RD; Nassiri I; Cooper R; Taylor CA; Akbani U; Brain O; Matin RN; Coupe N; Middleton MR; Coles M; Sacco JJ; Payne MJ; Fairfax BP
Br J Cancer; 2021 May; 124(10):1661-1669. PubMed ID: 33723392
[TBL] [Abstract][Full Text] [Related]
40. Assessment of hospitalization rates for immune-related adverse events with immune checkpoint inhibitors.
Nice L; Bycroft R; Wu X; Rai SN; Figg L; Bhandari S; Burd M
J Oncol Pharm Pract; 2021 Oct; 27(7):1736-1742. PubMed ID: 33100180
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
